Bacteriophages and Coronavirus Disease (COVID-19)
The decrease of bacterial growth and the covalent binding of synthetic antibodies to viruses - both goals can be achieved by bacteriophages
The decrease of bacterial growth and the covalent binding of synthetic antibodies to viruses - both goals can be achieved by bacteriophages
It was demonstrated that phage K1F can infect intracellular E. coli EV36 within hCMECs without themselves eliciting an inflammatory or defensive response
In light of the novel coronavirus, scientists and researchers from all over the globe have been looking at traditional and non-traditional methods to develop a vaccine or treatment, some have led towards bacteriophages and Covid19
DNA from diverse ecosystems was sequenced and hundreds of phage genomes with lengths of more than 200 kilobases (kb), including a genome of 735 kb, were found
The phanorod strategy integrates the highly evolved targeting strategies of phages with the photothermal properties of gold nanorods, creating a well-controlled platform for systematic killing of bacterial cells
The product in the trial works through a unique dual mechanism of action utilizing both the natural lytic activity of the bacteriophage along with the DNA-targeting activity of CRISPR-Cas3
Phages bind both to porcine mucus and to rainbow trout (Oncorhynchus mykiss) primary mucus, persist up to 7 days in the mucosa, and provide protection against Flavobacterium columnare
Bacteriophages that target cytolytic E. faecalis decrease cytolysin in the liver and abolish ethanol-induced liver disease in humanized mice
Phages can cause phage-specific immune responses. That suggests that a specific phage could be optimally selected for use in phage therapy, considering both its anti-bacterial activity and the type of immune response it may evoke
Vastly diverse phage libraries containing more than a million of different members were created. Structure-informed engineering of viral tail fibers generated host-range alterations
This review presents comprehensive data about phage therapy in the treatment of mycobacterial infection, specifically tuberculosis disease
This year was the 23rd Evergreen conference and it covered almost everything you could think of when it comes to phage
These results contribute relevant information to the adoption of phage therapy as an alternative to growth-promoter antibiotics on poultry farms
Phage administration was effective in reducing viable E. coli in infected mice with a similar efficacy to ampicillin therapy. However, the F.O.P. bacteriophage preparation had less impact on the gut microbiota compared to ampicillin
One promising technique is bacteriophage biocontrol, a green and natural method that uses lytic bacteriophages isolated from the environment to specifically target pathogenic bacteria and eliminate them from (or significantly reduce their levels in) foods
Bacteriophages are essentially bionanoparticles with a protein coat, the building blocks for bottom-up synthesis of multifunctional materials with advanced properties
Some current studies that have addressed synergistic killing activity between phages and antibiotics, the issues of treatment order and antibiotic class, and point to considerations that will have to be addressed by future studies are discussed
The work offered the proof of concept of phage therapy to manipulate transient as well as indigenous bacterial flora in gut‐related dysbiosis of turtles
The rapid lysis of bacteria by bacteriophages in vivo does not increase the innate inflammatory response compared to antibiotic treatment
Bacterial viruses (phages) have been recognized increasingly as immunomodulators contributing to immune homeostasis and curbing inflammation
A 15-year-old patient with cystic fibrosis with a disseminated Mycobacterium abscessus infection was treated with a three-phage cocktail following bilateral lung transplantation
Effects of a cocktail of Escherichia coli-targeting bacteriophages on gut microbiota and markers of intestinal and systemic inflammation in a healthy human population were examined
The Perfect Predator by Steffanie Strathdee and Tom Patterson – а bracing medical thriller about one woman’s race to save her husband from a lethal, antibiotic-resistant superbug
A patient with a trauma-related left tibial infection associated with XDR Acinetobacter baumannii and MDR Klebsiella pneumoniae was treated with bacteriophages and antibiotics
A new study shows that bacteriophages can be used to fight Pseudomonas aeruginosa, the most common bacteria found in cystic fibrosis patients
Scientists from University College Cork review the composition and physiological relevance of human gut bacteriophages
Antibiotics need to be used with care to preserve their effectiveness for when they are truly needed
Data obtained strongly suggest that phages may induce immunomodulatory effects which can be used in the clinic in phagotherapy
Pseudomonas aeruginosa phage cocktail in a sheep model of rhinosinusitis was able to decrease sinus pathogen biofilm. No safety concerns were noted
Phage therapy constitutes a very promising approach in the control of topical microbial populations
A new study shows that these pathogenic bacteria can be killed cheaply and quickly by a combined treatment with sunlight and bacteria-killing viruses called bacteriophages
Two phage clinical trials will launch in the USA in 2019. The trials will evaluate the safety, tolerability and efficacy of experimental bacteriophage therapy in people with Crohn's disease and VADs infected by resistant S. aureus
Researchers from across disciplines at Charles River discuss which trends they expect will propel the development of novel therapeutics forward this year. Phage Therapy one of the Top 10 Drug Discovery Trends to Watch in 2019
The 3rd Microbiome Movement – Drug Development Europe (28-30 January 2019) returns as the industry-defining forum to help discover, develop and deliver the next generation of microbiome-based therapeutic and diagnostic candidates to market
A nationwide study in Denmark have shown the association between treated infections and the subsequent risk of treated mental disorders in children and adolescent
Phage treatment has high specificity when combating Salmonella infection and offers a noninvasive alternative to antibiotic treatment
Princeton biologists have identified a virus, VP882, that can listen in on bacterial conversations - and then they found a way to use that to make it attack bacterial diseases like E. coli and cholera
ResistanceMap is an open interactive collection of charts and maps that summarize national and subnational data on antimicrobial use and resistance worldwide
Phagoburn is a project funded by the European Union under the 7th Framework Programme for Research and Development. Phagoburn was launched on June 1st, 2013
In the latest market report the global bacteriophage market was valued at US$ 567.9 Mn in 2017 expanding at a CAGR of 3.9% from 2018 to 2026